Incannex Healthcare Limited (IXHL)
USD 0.13
(-0.15%)
USD 0.13
(-0.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -18.45 Million USD | 62.18% |
| 2023 | -19.97 Million AUD | -34.06% |
| 2022 | -14.9 Million AUD | -74.42% |
| 2021 | -8.54 Million AUD | -164.72% |
| 2020 | -3.22 Million AUD | -18.74% |
| 2019 | -2.71 Million AUD | 7.79% |
| 2018 | -2.94 Million AUD | 86.28% |
| 2017 | -21.49 Million AUD | -2611.6% |
| 2016 | -792.59 Thousand AUD | 68.77% |
| 2015 | -2.53 Million AUD | 78.77% |
| 2014 | -11.95 Million AUD | 0.76% |
| 2013 | -12.04 Million AUD | -284.84% |
| 2012 | -3.13 Million AUD | 32.35% |
| 2011 | -4.62 Million AUD | -282.85% |
| 2010 | 2.53 Million AUD | 165.34% |
| 2009 | -3.87 Million AUD | -251.82% |
| 2008 | -1.1 Million AUD | -3.65% |
| 2007 | -1.06 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -6.46 Million USD | -23.28% |
| 2024 Q3 | -6.03 Million USD | -15.07% |
| 2024 Q2 | -5.24 Million USD | -25.56% |
| 2024 Q1 | -727 Thousand USD | 90.6% |
| 2023 Q3 | -3.57 Million USD | -22.38% |
| 2023 Q2 | -2.91 Million USD | 92.35% |
| 2023 Q1 | -38.14 Million USD | -449.49% |
| 2023 Q4 | -7.73 Million USD | -116.62% |
| 2023 FY | -19.97 Million AUD | -34.06% |
| 2022 FY | -14.9 Million AUD | -74.42% |
| 2022 Q4 | -6.94 Million USD | 0.0% |
| 2021 FY | -8.54 Million AUD | -164.72% |
| 2020 FY | -3.22 Million AUD | -18.74% |
| 2019 FY | -2.71 Million AUD | 7.79% |
| 2018 FY | -2.94 Million AUD | 86.28% |
| 2017 FY | -21.49 Million AUD | -2611.6% |
| 2016 FY | -792.59 Thousand AUD | 68.77% |
| 2016 Q3 | -198.14 Thousand AUD | 68.77% |
| 2016 Q4 | -198.14 Thousand AUD | 0.0% |
| 2016 Q1 | -634.47 Thousand AUD | 0.0% |
| 2016 Q2 | -634.47 Thousand AUD | 0.0% |
| 2015 Q1 | -2.98 Million AUD | 0.0% |
| 2015 FY | -2.53 Million AUD | 78.77% |
| 2015 Q4 | -634.47 Thousand AUD | 0.0% |
| 2015 Q3 | -634.47 Thousand AUD | 78.77% |
| 2015 Q2 | -2.98 Million AUD | 0.0% |
| 2014 Q2 | -3.01 Million AUD | 0.0% |
| 2014 FY | -11.95 Million AUD | 0.76% |
| 2014 Q3 | -2.98 Million AUD | 0.76% |
| 2014 Q4 | -2.98 Million AUD | 0.0% |
| 2014 Q1 | -3.01 Million AUD | 0.0% |
| 2013 Q4 | -3.01 Million AUD | 0.0% |
| 2013 Q1 | -782.67 Thousand AUD | 0.0% |
| 2013 Q2 | -782.67 Thousand AUD | 0.0% |
| 2013 FY | -12.04 Million AUD | -284.84% |
| 2013 Q3 | -3.01 Million AUD | -284.84% |
| 2012 FY | -3.13 Million AUD | 32.35% |
| 2012 Q4 | -782.67 Thousand AUD | 0.0% |
| 2012 Q3 | -782.67 Thousand AUD | 33.71% |
| 2012 Q2 | -1.18 Million AUD | 0.0% |
| 2012 Q1 | -1.18 Million AUD | 0.0% |
| 2011 Q4 | -1.18 Million AUD | 0.0% |
| 2011 FY | -4.62 Million AUD | -282.85% |
| 2011 Q3 | -1.18 Million AUD | -296.07% |
| 2011 Q1 | 602.17 Thousand AUD | 0.0% |
| 2011 Q2 | 602.17 Thousand AUD | 0.0% |
| 2010 Q3 | 602.17 Thousand AUD | 162.19% |
| 2010 Q4 | 602.17 Thousand AUD | 0.0% |
| 2010 FY | 2.53 Million AUD | 165.34% |
| 2010 Q1 | -968.31 Thousand AUD | 0.0% |
| 2010 Q2 | -968.31 Thousand AUD | 0.0% |
| 2009 Q1 | -278.28 Thousand AUD | 0.0% |
| 2009 Q4 | -968.31 Thousand AUD | 0.0% |
| 2009 Q2 | -278.28 Thousand AUD | 0.0% |
| 2009 Q3 | -968.31 Thousand AUD | -247.96% |
| 2009 FY | -3.87 Million AUD | -251.82% |
| 2008 Q3 | -278.28 Thousand AUD | -4.17% |
| 2008 Q1 | -267.14 Thousand AUD | 0.0% |
| 2008 FY | -1.1 Million AUD | -3.65% |
| 2008 Q4 | -278.28 Thousand AUD | 0.0% |
| 2008 Q2 | -267.14 Thousand AUD | 0.0% |
| 2007 Q3 | -267.14 Thousand AUD | 0.0% |
| 2007 FY | -1.06 Million AUD | 0.0% |
| 2007 Q4 | -267.14 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 91.178% |
| Theratechnologies Inc. | -23.95 Million USD | 22.949% |
| Safety Shot Inc | -15.08 Million USD | -22.382% |
| Cosmos Health Inc. | -18.54 Million USD | 0.451% |
| Cronos Group Inc. | -73.96 Million USD | 75.043% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.158% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 56.257% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 473.286% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -199.51% |
| ProPhase Labs, Inc. | -16.78 Million USD | -9.993% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -281.779% |
| Dynavax Technologies Corporation | -6.38 Million USD | -188.918% |
| Radius Health, Inc. | -25.79 Million USD | 28.429% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -495.734% |
| Alvotech | -551.73 Million USD | 96.654% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -309.65% |
| Alpha Teknova, Inc. | -36.78 Million USD | 49.812% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 86.784% |
| SCYNEXIS, Inc. | 67.04 Million USD | 127.534% |
| Harrow Health, Inc. | -24.41 Million USD | 24.382% |
| Biofrontera Inc. | -20.13 Million USD | 8.306% |
| DURECT Corporation | -27.62 Million USD | 33.178% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1502.66% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 198.296% |
| OptiNose, Inc. | -35.48 Million USD | 47.978% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 177.183% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -134.549% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -193.965% |
| SIGA Technologies, Inc. | 68.06 Million USD | 127.118% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 253.659% |
| Shineco, Inc. | -22.44 Million USD | 17.774% |
| Phibro Animal Health Corporation | 2.41 Million USD | 864.031% |
| Procaps Group S.A. | 42.54 Million USD | 143.392% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -79.597% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -329.096% |
| Viatris Inc. | 54.7 Million USD | 133.746% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -309.65% |
| Rockwell Medical, Inc. | -8.43 Million USD | -118.734% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -16.505% |
| Tilray Brands, Inc. | -244.98 Million USD | 92.465% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 138.332% |
| PetIQ, Inc. | 2.13 Million USD | 966.213% |
| Silver Spike Investment Corp. | 7.34 Million USD | 351.481% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 107.392% |
| Journey Medical Corporation | -3.85 Million USD | -379.081% |
| Alimera Sciences, Inc. | -20.13 Million USD | 8.31% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -126.125% |
| Assertio Holdings, Inc. | -331.94 Million USD | 94.439% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -179.991% |
| Embecta Corp. | 70.4 Million USD | 126.22% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 7.969% |
| Procaps Group, S.A. | 42.54 Million USD | 143.392% |
| PainReform Ltd. | -9.34 Million USD | -97.549% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 88.483% |
| Hempacco Co., Inc. | -13.12 Million USD | -40.628% |
| Talphera, Inc. | -18.39 Million USD | -0.337% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 143.997% |
| Alvotech | -551.73 Million USD | 96.654% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 105.651% |
| Kamada Ltd. | 8.28 Million USD | 322.827% |
| Indivior PLC | 2 Million USD | 1022.95% |
| Currenc Group, Inc. | -15.3 Million USD | -20.595% |
| Evoke Pharma, Inc. | -7.79 Million USD | -136.888% |
| Flora Growth Corp. | -57.03 Million USD | 67.636% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 7.969% |
| Evolus, Inc. | -61.68 Million USD | 70.075% |
| HUTCHMED (China) Limited | 100.78 Million USD | 118.316% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 113.42% |
| Akanda Corp. | -32.27 Million USD | 42.807% |